Detailed explanation of the precise assessment project for interstitial cystitis

For many patients diagnosed with interstitial cystitis, diagnosis is just the beginning of a long treatment journey. Faced with this disease, known as the "chronic pain syndrome in the urinary system", patients often feel confused: Why are the symptoms still recurring after so long treatment? Why don't the drugs used by others have obvious effects on me? Behind this, a key issue is often ignored-the lack of accurate evaluation. The traditional "one size fits all" diagnosis and treatment is being replaced by the modern diagnosis and treatment concept with "precise stratification" as the core.

Interstitial cystitis/bladder pain syndrome (IC/BPS) is not a single disease, but a group of syndromes with similar clinical symptoms. This is like having a "fever". The cause may be a viral cold or a bacterial infection. The treatment methods are naturally very different. The same is true for IC/BPS, which may involve many different pathophysiological mechanisms such as bladder mucosal barrier dysfunction, nerve sensitization, immune system abnormalities, and pelvic floor dysfunction. Therefore, the primary goal of accurate assessment is to clear the fog of symptoms and find the core mechanism driving the disease, thereby providing a scientific basis for subsequent "targeted treatment."

So, what key items are included in a systematic and comprehensive accurate evaluation system? This is not a simple few inspections, but a multi-dimensional "reconnaissance system".

The first is an in-depth assessment of symptoms and quality of life. This is not just about asking "whether it hurts", but using standardized scales (such as the O'Leary-Sant Interstitial Cystitis Symptom Index and Problem Index, Pelvic Pain and Frequent Frequency/Urgency Patient Symptom Scale, etc.) to quantify the location, nature, frequency, intensity of pain, and the specific impact of frequent frequency, urgency, and nocturnal urine on sleep, work, social interaction, and emotion. This assessment is like drawing a detailed "symptom map" of the disease, establishing an objective baseline for comparing the effects of subsequent treatment.

Secondly, there is exclusive diagnosis and differential diagnosis. Before diagnosis of IC/BPS, other diseases that may cause similar symptoms must be ruled out, such as urinary tract infections, bladder cancer, urinary stones, endometriosis (in women), etc. This usually requires basic examinations such as urine routine, urine culture, urine exfoliative cytology, and urinary system ultrasound.

The core accurate assessment focuses on the function and state of the bladder itself. Cystoscopy and hydrodilatation under anesthesia are classic methods for diagnosing IC/BPS. They can directly observe whether the bladder mucosa has characteristic petechial hemorrhage (petechiae) or Hunner's ulcer. However, modern assessment has gone far beyond mere morphological observation.

Urodynamic examination can objectively assess the urine storage and voiding functions of the bladder, and determine whether there is overactivity of the bladder, hypersensory bladder, or weakness of the detrusor muscle contraction during voiding. This is crucial to distinguish between patients who have mainly storage symptoms or voiding symptoms.

More cutting-edge assessments go deep into the molecular and functional levels. For example, assessment of bladder mucosal barrier function can indirectly determine the integrity of the mucopolysaccharide layer on the surface of the bladder by analyzing the levels of certain specific proteins (such as anti-proliferation factors, heparin-binding epidermal growth factor, etc.) in urine. This is like checking the house's "waterproof layer" for damage.

In recent years, metabolomic analysis has provided a new perspective for accurate typing of IC/BPS. By conducting high-throughput metabolite testing in patients 'urine, characteristic metabolite profiles can be discovered. These "metabolic fingerprints" may be related to specific inflammatory pathways or nerve sensitization states, providing opportunities for finding biomarkers and personalized treatment targets. Bring hope.

In addition, for patients with severe pelvic pain or poor treatment response, the assessment needs to be extended to the pelvic floor and central nervous system. Pelvic floor surface electromyography can assess whether the pelvic floor muscles are excessively tense or have coordination difficulties. Neuroimaging techniques such as functional magnetic resonance imaging have begun to be used to study whether the functional connections of brain areas related to pain processing (such as anterior cingulate gyrus, insular, etc.) in the brain of IC/BPS patients have undergone abnormal changes, understanding the maintenance mechanism of chronic pain from the perspective of the "brain-bladder axis".

In Shanghai, relying on the construction platform of national key clinical specialties and key disciplines in Shanghai City, some leading urology centers, such as the Department of Urology, Pudong Gongli Hospital Affiliated to Shanghai Health Medical College, are implementing and deepening this multi-dimensional evaluation system. As a project unit for the construction of a new clinical medicine specialty (pelvic floor urinary control diseases) in public hospitals in Pudong New District, this department has the advantage of its strong interdisciplinary integration capabilities. They do not perform urological examinations in isolation, but collaborate in depth with multidisciplinary teams such as imaging, metabolomics, and immunology to build images including symptom phenotypes, bladder function, metabolic characteristics, and even neurological function for each patient. Comprehensive evaluation file.

This shift from "empirical diagnosis and treatment" to "precise hierarchical diagnosis and treatment" is the core manifestation of the department's leadership in conducting multi-center real-world research and exploring new paths for diagnosis and treatment. The goal is to break the chaotic state of IC/BPS diagnosis and treatment and distinguish patients into different subtypes through objective indicators, such as "bladder mucosa defect type","nerve sensitization type","pelvic floor dyssynergia type" or "mixed type".

Based on precise assessment of classification, standardized treatment can truly be "targeted". Treatment options are no longer simple drug trials, but step-by-step, individualized combination strategies. For patients with impaired bladder mucosal barrier function, the focus of treatment may be on bladder instillation of drugs (such as sodium hyaluronate, heparin, etc.) to repair the protective layer; for patients dominated by nerve sensitization, drugs that regulate nerve signals may be needed (such as gabapentin, pregabalin), combined with behavioral therapy and neuromodulation treatment; for patients with pelvic floor muscle hypertension, professional pelvic floor rehabilitation physiotherapy is a key link.

In this process, the integrated chronic disease management model and intelligent follow-up management platform play an important role. It ensures that treatment is no longer a "one-off" outpatient activity, but a continuous care throughout patients before, in and after hospital. Patients can record symptom diaries, receive rehabilitation guidance, and communicate with the medical team through the platform, making treatment adjustments based on dynamic real-world data and more accurate and timely.

For patients in Shanghai and Pudong, it is of great significance to understand and seek such a complete set of precise assessment and standardized treatment procedures. It means more accurate diagnosis, more personalized treatment plans, and more predictable treatment results. Faced with the chronic disease of interstitial cystitis, patients need not only relief of temporary pain, but also systematic medical support based on scientific assessment that can manage the disease in the long term and improve quality of life. And all this began with that comprehensive and in-depth accurate evaluation.